Loxiglumide Rotta Research

IDrugs

Volumn 5, Issue 5, 2002, Pages 469-474

  Katschinski, Martin ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; DEXLOXIGLUMIDE; LOXIGLUMIDE; PLACEBO; PROGLUMIDE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG URINE LEVEL; EATING DISORDER; ENTERITIS; EXPERIMENTAL MODEL; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PANCREATITIS; REVIEW; STOMACH FUNCTION DISORDER; STRUCTURE ACTIVITY RELATION;

EID: 0141449202     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 77273 Anticholecystokinin activities of loxiglumide. Setnikar I, Bani M, Cereda R et al. Arzneimittelforschung 1987 37 10 1168-1171
2. 77274 Loxiglumide protects against experimental pancreatitis. Setnikar I, Bani M, Cereda R, Chiste R, Makovec F, Pacini MA, Revel L Arzneimittelforschung 1987 37 10 1172-1174
3. 80334 Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Setnikar I, Chiste R, Makovec F, Rovati LC, Warrington SJ Arzneimittelforschung 1988 38 5 716-720
4. 87338 Role of cholecystokinin in regulation of gastrointestinal motor functions. Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JBMJ, Zach D, Rovati LC, Stalder GA Lancet 1989 2 8653 12-15
5. 87363 Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Otsuki M, Fujii M, Nakamura T, Okabayashi Y, Tani S, Fujisawa T, Koide M, Baba S Dig Dis Sci 1989 34 6 857-864
6. 89833 Pharmacokinetics and tolerance of repeated oral doses of loxiglumide. Setnikar I, Chiste R, Giacovelli G, Rovati LC Arzneimittelforschung 1989 39 11 1454-1459
7. 93362 Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man. Jansen JBMJ, Masclee AAM, Lamers CBHW Br J Clin Pharmacol 1990 29 6 770-773
8. 102403 Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans: Studies with the cholecystokinin-receptor antagonist loxiglumide. Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A, Stalder GA, Rovati L Gastroenterology 1991 101 2 503-511
9. 104919 Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokin receptor antagonist loxiglumide. Fried M, Schwizer W, Beglinger C, Keller U, Jansen JB, Lamers CB Diabetologia 1991 34 10 721-726
10. 115027 Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats. Taguchi S, Green GM, Nakano I, Hatta Y Int J Pancreatol 1992 11 67-73
11. 133830 Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer. Morimoto H, Nio Y, Tsubuno M, Tseng CC, Kawabata K, MasaiY, Hayashi H, Baba N, Manabe T, Hosokawa Y, et al. J Surg Oncol 1993 53 47-53
12. 140397 Treatment of chronic constipation in geriatric patients with loxiglumide (Lox), a cholecystokinin antagonist. Meier R, Thumshirn M, Meyer B, Rovati LC, Gyr K, Beglinger C Gastroenterology 1990 98 A374
13. 190133 Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. Lieverse RJ, Masclee AAM, Jansen JBMJ, Rovati LC, Lamers CBHW Biol Psychiatry 1995 37 5 331-335
14. 201782 CCK/gastrin antagonists-clinical perspectives. Calam J Acta Gastro Enterol Belg 1993 56 3-4 251-256
15. 201788 Cholecystokinin does not delay gastric emptying of regular meals in healthy humans. Niederau C, Mecklenbeck W, Heindges T Hepato Gastroenterol 1993 40 4 380-383
16. 216830 Drug development pipeline: UR-906, colestimide, QA-241, loxiglumide. Tokyo Tanabe Co Ltd Company Communication 1996 August 20
17. 238765 Intestinal phase of human antro-pyloro-duodenal motility: Cholinergic and CCK-mediated regulation. Katschinski M, Schirra J, Begliner C, Langbein S, Wank U, D'Amato M, Arnold R Eur J Clin Invest 26 7 574-583
18. 238766 Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Borovicka J, Kreiss C, Asal K, Remy B, Mettraux C, Wells A, Read NW, Jansen JB, D'Amato M, Delaloye AB, Fried M, Schwizer W Am J Physiol 1996 271 3 Pt 1 G448-G453
19. 238771 Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Feinle C, D'Amato M, Read NW Gastroenterology 1996 110 5 1379-1385
20. 238774 Studies on the synthesis of cholecystokinin a receptor antagonists. II. Synthesis and cholecystokinin a receptor inhibitory activities of sulfur- containing amide-carboxylic acid derivatives. Ajisawa Y, Kitazawa M, Nakano Y, Tsubaki A, Ban M, Sato K, Okazaki K, Kobayashi M Yakugaku Zasshi 1996 116 5 396-410
21. 247963 Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Militello C, Sperti C, DiPrima F, Pedrazzoli S Pancreas 1997 14 3 222-228
22. 251999 New Drugs in the R&D Pipeline - Tokyo Tanabe. Pharma Jpn 1997 1544 17
23. 282839 Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist. Fukamizu Y, Nakajima T, Kimura K, Kanda H, Fujii M, Saito T, Kasai H Arzneimittelforschung 1998 48 1 58-64
24. 282852 Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans. Boulant J, Mathieu S, D'Amato M, Abergel A, Dapoigny M, Bommelaer G Gut 1997 40 5 575-581
25. 282853 Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: Studies with the CCK antagonist loxiglumide. Schwizer W, Borovicka J, Kunz P, Fraser R, Kreiss C, D'Amato M, Crelier G, Boesiger P, Fried M Gut 1997 41 4 500-504
26. 338523 R&D pipeline. Kaken Pharmaceutical Co Ltd Company World Wide Web Site 1999 September 01
27. 365460 Development pipeline. Mitsubishi Tokyo Pharmaceuticals Inc Company World Wide Web Site 2000 February 01
28. 370620 Drug development pipeline: Loxiglumide and dexloxiglumide. Rotta Research Lab SpA Company Communication 2000 June 07
29. 370628 Physiological role of cholecystokinin in gastroprotection in humans. Konturek JW, Hengst K, Konturek SJ, Sito E, Stachura J, Domschke W Am J Gastroenterol 1998 93 12 2385-2390
30. 370631 Involvement of cholecystokinin A receptors in transient lower esophageal sphrincter relaxations triggered by gastric distension. Boeckxstaens GE, Hirsch DP, Fakhry N, Holloway RH, D'Amato M, Tytgat GN Am J Gastroenterol 1998 93 10 1823-1828
31. 370632 Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Clave P, Gonzalez A, Moreno A, Lopez R, Farre A, Cusso X, D'Amato M, Aspiroz F, Lluis F Gastroenterology 1998 115 3 597-604
32. 371091 Development pipeline. Mitsubishi Tokyo Pharmaceuticals Inc Company World Wide Web Site 2000 March 31
33. 411053 R&D pipeline. Kaken Pharmaceutical Co Ltd Company world Wide Web Site 2001 May 30
34. 422712 New drugs in the R&D pipeline: Mitsubishi-Tokyo Pharmaceutical. Pharma Jpn 2001 1762 September 17 29
35. 423717 Mitsubishi Pharma Corp. Welfide Corp Company World Wide Web Site 2001 October 01
36. 428502 The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Trudgill NJ, Hussain FN, Moustafa M, Ajjan R, D'Amato M, Riley SA Aliment Pharmacol Ther 2001 15 9 1357-1364
37. 430428 Development pipeline. Mitsubishi Pharma Corp Company World Wide Web Site 2001 November 23
38. 1 receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. D'Amato M, Whorwell PJ, Thompson DG, Spiller RC, Giacovelli G, Griffin PH Am J Gastroenterol 2001 96 9 S317
39. 443498 Effect of cholecystokinin-A receptor blockade on lipid-induced gastric relaxation in humans. Mesquita MA, Thompson DG, Troncon LE, D'Amato M, Rovati LC, Barlow J Am J Physiol 1997 273 1 118-123
40. 449395 Oral administration of CCK antagonist loxiglumide inhibits postprandial gallbladder contraction without affecting gastric emptying. Corazziari E, Ricci E, Biliotti D,. Bontempo I, Pallotta N, Torsoli A Dig Dis Sci 1990 35 4 50-54
41. 449397 Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Chua AS, Bekkering M, Rovati LC, Keeling PW Ann N Y Acad Sci 1994 713 451-453
42. 449398 Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: Studies with the CCK antagonist loxiglumide. Schqizer W, Brovicka J, Kunz P, Fraser R, Kreiss C, D'Amato M, Crelier G, Boesiger P, Fried M Gut 1997 41 4 500-504
43. 449403 Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Cann PA, Rovati LC, Smart H, Spiller RC, Whorwell PJ Ann N Y Acad Sci 1994 713 449-450
44. 449408 Endogenous cholecystokinin in postprandial lower esophageal sphincter and fundic tone in humans. Zerbib F, Bruley Des Varannes SM, Scarpignato C, Leray V, D'Amato M, Roze C, Galmiche JP Am J Physiol 1998 275 6 Pt 1 G1266-G1273
45. 449413 Effect of CCK-A receptor blockade on esophageal motility. Katschinski M, Schirra J, Koppelberg T, Arnold R, Rovati LC, Beglinger C, Adler G Eur J Gastroenterol Hepatol 1994 6 983-986
46. 49429 Clinical evaluation of oral administration of a CCK-A receptor antagonist (loxiglumide) to patients with acute painful attacks of chronic pancreatitis: A multicenter dose-response study in Japan. Shiratori K, Takeuchi T, Sagake K, Matsuno S, Pancreas 2002 24 5
47. 449509 Drug development pipeline: Loxiglumide. Rotta Research Lab SpA Company Communication 2002 April 26
48. 450719 In-depth report: Petrochemical industry monthly. Watabe T Merrill Lynch & Co 2001 December 26